TREATMENT OF LARGE HCC - TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION COMBINED WITH PERCUTANEOUS ETHANOL INJECTION VERSUS REPEATED TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION

被引:155
作者
BARTOLOZZI, C
LENCIONI, R
CARAMELLA, D
VIGNALI, C
CIONI, R
MAZZEO, S
CARRAI, M
MALTINTI, G
CAPRIA, A
CONTE, PF
机构
[1] SANTA CHIARA UNIV HOSP,DEPT INTERNAL MED 2,I-56125 PISA,ITALY
[2] SANTA CHIARA UNIV HOSP,DEPT INTERNAL MED 1 & GASTROENTEROL,I-56125 PISA,ITALY
[3] SANTA CHIARA UNIV HOSP,DEPT ONCOL,I-56125 PISA,ITALY
[4] CISANELLO UNIV HOSP,DEPT GASTROENTEROL,PISA,ITALY
关键词
ALCOHOL; LIVER; INTERVENTIONAL PROCEDURE; LIVER NEOPLASMS; CHEMOTHERAPEUTIC INFUSION; THERAPY;
D O I
10.1148/radiology.197.3.7480761
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
PURPOSE: To compare the efficacy of transcatheter arterial chemoembolization (TACE) combined with percutaneous ethanol injection (PEI) versus repeated TACE in the treatment of large hepatocellular carcinoma (HCC). MATERIALS AND METHODS: Fifty-three patients with cirrhosis and a large HCC (main tumor, 3.1-8.0 cm in diameter with no more than two daughter nodules) were enrolled in a prospective, randomized study. Twenty-six patients underwent a single TACE session followed by PEI (TACE-PEI group), whereas 27 patients underwent two to five TACE sessions (TACE group). Both groups of patients were similar with regard to Liver function. Follow-up ranged from 8 to 39 months. RESULTS: Complete therapeutic responses were higher (P < .05) and tumor recurrences during follow-up were lower (P < .05) in the TACE-PEI group than in the TACE group. Patients in the TACE-PEI group survived longer than those in the TACE group, although the difference was not significant (P > .1). The rates of survival without recurrence were better in the TACE-PEI group than in the TACE group (P < .05). CONCLUSION Use of a single TACE session combined with PEI is more effective than repeated TACE in the treatment of large HCC.
引用
收藏
页码:812 / 818
页数:7
相关论文
共 42 条
[1]   PROGNOSIS OF UNRESECTABLE HEPATOCELLULAR-CARCINOMA - AN EVALUATION BASED ON MULTIVARIATE-ANALYSIS OF 90 CASES [J].
AKASHI, Y ;
KOREEDA, C ;
ENOMOTO, S ;
UCHIYAMA, S ;
MIZUNO, T ;
SHIOZAKI, Y ;
SAMESHIMA, Y ;
INOUE, K .
HEPATOLOGY, 1991, 14 (02) :262-268
[2]   NATURAL-HISTORY OF SMALL UNTREATED HEPATOCELLULAR-CARCINOMA IN CIRRHOSIS - A MULTIVARIATE-ANALYSIS OF PROGNOSTIC FACTORS OF TUMOR-GROWTH RATE AND PATIENT SURVIVAL [J].
BARBARA, L ;
BENZI, G ;
GAIANI, S ;
FUSCONI, F ;
ZIRONI, G ;
SIRINGO, S ;
RIGAMONTI, A ;
BARBARA, C ;
GRIGIONI, W ;
MAZZIOTTI, A ;
BOLONDI, L .
HEPATOLOGY, 1992, 16 (01) :132-137
[3]   HEPATOCELLULAR-CARCINOMA - CT AND MR FEATURES AFTER TRANSCATHETER ARTERIAL EMBOLIZATION AND PERCUTANEOUS ETHANOL INJECTION [J].
BARTOLOZZI, C ;
LENCIONI, R ;
CARAMELLA, D ;
FALASCHI, F ;
CIONI, R ;
DICOSCIO, G .
RADIOLOGY, 1994, 191 (01) :123-128
[4]  
BRONOWICKI JP, 1994, CANCER, V76, P16
[5]   PHASE-II STUDY OF TRANSARTERIAL EMBOLIZATION IN EUROPEAN PATIENTS WITH HEPATOCELLULAR-CARCINOMA - NEED FOR CONTROLLED TRIALS [J].
BRUIX, J ;
CASTELLS, A ;
MONTANYA, X ;
CALVET, X ;
BRU, C ;
AYUSO, C ;
JOVER, L ;
GARCIA, L ;
VILANA, R ;
BOIX, L ;
RODES, J .
HEPATOLOGY, 1994, 20 (03) :643-650
[6]  
CASTELLS A, 1993, HEPATOLOGY, V18, P1121
[7]  
CHANG JM, 1994, CANCER, V74, P2449, DOI 10.1002/1097-0142(19941101)74:9<2449::AID-CNCR2820740910>3.0.CO
[8]  
2-4
[9]   HEPATOCELLULAR-CARCINOMA IN ITALIAN PATIENTS WITH CIRRHOSIS [J].
COLOMBO, M ;
DEFRANCHIS, R ;
DELNINNO, E ;
SANGIOVANNI, A ;
DEFAZIO, C ;
TOMMASINI, M ;
DONATO, MF ;
PIVA, A ;
DICARLO, V ;
DIOGUARDI, N .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 325 (10) :675-680
[10]  
EBARA M, 1986, GASTROENTEROLOGY, V90, P259